Related Experiment Videos

Recurrent stroke and vascular events in elderly patients with anticardiolipin antibodies: a prospective study

O Heinzlef1, N Abuaf, A Cohen

  • 1Department of Neurology, Vasculaire Saint Antoine Hospital, Paris, France.

Insights

In elderly patients, anticardiolipin antibodies (aCL) do not appear to increase the risk of recurrent vascular events, unlike in younger individuals. This study found no significant difference in stroke recurrence between elderly patients with and without elevated aCL levels.

Area of Science:

  • Neurology
  • Immunology
  • Cardiology

Background:

  • Anticardiolipin antibodies (aCL) are known stroke risk factors in young patients.
  • The role of aCL in vascular event risk among the elderly is unclear.

Purpose of the Study:

  • To assess the frequency of aCL in elderly stroke patients.
  • To determine if aCL positivity predicts recurrent stroke or vascular events in patients over 60.

Main Methods:

  • Evaluated 242 patients over 60 years old admitted for brain infarction.
  • Measured aCL immunoreactivity (ELISA, IgG antiphospholipid units) and performed transoesophageal echocardiography.
  • Followed patients for a mean of 2.33 years to track recurrent vascular events.

Main Results:

  • 21% of patients had at least 10 GPL units of aCL.
  • No significant differences in echocardiographic findings between aCL-positive and negative groups.
  • Recurrent stroke incidence was 4.5/100 person-years (aCL >10 GPL) vs. 2.7/100 person-years (aCL <10 GPL).
  • Kaplan-Meier analysis showed no difference in overall vascular events between groups.

Conclusions:

  • Elderly patients with 10 or more GPL units of aCL and negative for anti-beta2 glycoprotein I do not exhibit an increased risk of vascular events.
  • Findings contrast with the established risk associated with aCL in younger populations.

Related Concept Videos